Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Celltrion Expands Omlyclo® Portfolio in Europe with Launch of 300 mg Strength

25 August 2026 · By · Wire by Fusion42

Published

25 August 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

Europe

◆ Source

Read at pressreleasehub.pa.media →

◆ Verified

Fusion42 · 25 August 2026 · Fusion42 review

Celltrion launched a 300 mg strength of its biosimilar drug Omlyclo® (omalizumab) in key European markets including Germany, the UK, and France, expanding its portfolio with multiple dose strengths and device options to offer treatment flexibility.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You now face a larger biosimilar market with more flexible dosing options thanks to Celltrion’s new Omlyclo® 300 mg. This expansion opens sales doors in major European countries, making competition more urgent and varied.

◆ Coverage

1 source · 25 Aug 2026

◆ Related on Wire

◆ Topics

Biotechbiosimilaromalizumabeurope-launchportfolio-expansiondose-flexibility